Market
Understand market structure changes, launch dynamics, and access shifts that affect asset and company valuations.
11 signals
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
STRATEGY
The budget impact of dostarlimab combined with carboplatin-paclitaxel as a first-line treatment for endometrial cancer was assessed.
STRATEGY
Finotonlimab plus bevacizumab showed increased survival benefits but was not cost-effective compared to sorafenib.
COMPETITIVE
Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for Empagliflozin.
COMPETITIVE
Sandoz Inc. has submitted ANDA219346 for review, classified as a standard priority application.
COMPETITIVE
Amneal Pharmaceuticals has submitted a supplemental abbreviated new drug application (ANDA) for Capecitabine.
STRATEGY
Hetero Labs Limited has submitted ANDA220421 for Vemagal, currently under standard review.
STRATEGY
The systematic literature review evaluates health-related outcomes of nirmatrelvir/ritonavir treatment for COVID-19.
COMPETITIVE
Apotex has submitted a supplemental abbreviated new drug application (ANDA) for Pomalidomide.
STRATEGY
Replacing the standard influenza vaccine with the adjuvanted version in older adults could save €4.3-12.8 million and gain 2,220-6,659 QALYs.
STRATEGY
The study evaluates the cost-effectiveness of mavacamten combined with standard therapies for symptomatic obstructive HCM.
COMPETITIVE
Aiping Pharm Inc. has submitted an application (ANDA078499) for Topiramate with a standard review priority.
Showing 1–11 of 11 records